The national budget impact of managed entry agreement strategies match with high-cost drugs to maximise drug cost saving: a study protocol
Piyapat Owat, Chaoncin Sooksriwong, Hataiwan Ratanabunjerdkul, Tuangrat Phodha · 2024
Read The national budget impact of managed entry agreement strategies match with high-cost drugs to maximise drug cost saving: a study protocol by Piyapat Owat, Chaoncin Sooksriwong, Hataiwan Ratanabunjerdkul, Tuangrat Phodha (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616773.txt.
Description
Piyapat Owat and co-authors set out a 2024 study protocol on deals that can cut the national cost of pricey new drugs. Such deals, called managed entry agreements, are used in many countries to control drug spending. The study asks which kind of deal fits which kind of high cost drug, under uncertainty about price, use, and how well the drug works. The home setting for the question is a national health budget.
The plan mixes two parts: a quantitative study of procurement cost under each deal type, and a content analysis that matches deal types to drug traits. The authors argue that the right match can lower spending, keep the system sustainable, and widen patient access. They also warn that such deals are not right for every case. They should not be used as the standard way to set drug prices or pay for care, they say.
Catalog record
| CREATOR | Piyapat Owat, Chaoncin Sooksriwong, Hataiwan Ratanabunjerdkul, Tuangrat Phodha |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |